Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 194
- Registration Number
- NCT06408259
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇵🇹Centro Hospitalar E Universitário De Coimbra, Coimbra, Portugal
🇺🇸Local Institution - 0110, Phoenix, Arizona, United States
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT06363630
- Locations
- 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸Local Institution - 0001, Lenexa, Kansas, United States
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT06318676
- Locations
- 🇺🇸
PANAX, Miami Lakes, Florida, United States
🇺🇸Omega Research Group - Orlando, Orlando, Florida, United States
🇺🇸Orlando Clinical Research Center OCRC, Orlando, Florida, United States
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia
A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT06227975
- Locations
- 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT06170723
- Locations
- 🇺🇸
Local Institution - 0001, Tempe, Arizona, United States
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 156
- Registration Number
- NCT06163898
- Locations
- 🇺🇸
Local Institution - 0035, New Haven, Connecticut, United States
🇺🇸Local Institution - 0018, New York, New York, United States
🇺🇸Local Institution - 0033, Birmingham, Alabama, United States
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 618
- Registration Number
- NCT06045806
- Locations
- 🇫🇷
Local Institution - 0082, Paris, France
🇬🇷Local Institution - 0061, Athens, Attikí, Greece
🇬🇷Local Institution - 0062, Chaidari, Attikí, Greece
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha, Czechia
🇩🇪Local Institution - 0413, Dresden, Germany
🇩🇪Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany